Search

Your search keyword '"M. Provencio"' showing total 730 results
Start Over Author "M. Provencio"
730 results on '"M. Provencio"'

1. S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

Author

P. L. Zinzani, J. Mayer, R. Auer, F. Bijou, A. C. de Oliveira, C. R. Flowers, M. Merli, K. Bouabdallah, P. S. Ganly, Y. Song, H. Zhang, R. Johnson, A. M García-Sancho, M. Provencio, M. Trněný, S. Yuen, H. Tilly, E. Kingsley, G. Tuyman, S. E. Assouline, E. Ivanova, P. Kim, J. Huang, R. Delarue, and J. Trotman

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

2. ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Author

Zinzani, P. L., primary, Mayer, J., additional, Trotman, J., additional, Bijou, F., additional, de Oliveira, A. C., additional, Song, Y., additional, Zhang, Q., additional, Merli, M., additional, Bouabdallah, K., additional, Ganly, P. S., additional, Zhang, H., additional, Johnson, R., additional, Garcia‐Sancho, A. M., additional, Pulla, M. Provencio, additional, Trněný, M., additional, Yuen, S., additional, Assouline, S. E., additional, Auer, R., additional, Ivanoa, E., additional, Kim, P., additional, Greenbaum, A., additional, Huang, S., additional, Delarue, R., additional, and Flowers, C. R., additional

Published
2023
Full Text
View/download PDF

3. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations

Author

R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho, Pulmonary medicine, and CCA - Cancer Treatment and quality of life

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, Bevacizumab, Population, Phases of clinical research, bevacizumab, NSCLC, law.invention, T790M, Randomized controlled trial, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Osimertinib, education, Protein Kinase Inhibitors, education.field_of_study, Acrylamides, Aniline Compounds, business.industry, Standard treatment, Hematology, EGFR mutations, ErbB Receptors, osimertinib, Mutation, business, randomised controlled trial, medicine.drug
Abstract

Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations, progression inevitably occurs. The angiogenic pathway is implicated in EGFR TKI resistance. Patients and methods: BOOSTER is an open-label randomised phase II trial investigating the efficacy and safety of combined osimertinib 80 mg daily and bevacizumab 15 mg/kg every 3 weeks, versus osimertinib alone, in patients with EGFR-mutant advanced NSCLC and acquired T790M mutations after failure on previous EGFR TKI therapy. Primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR) and adverse events (AEs). Results: Between May 2017 and February 2019, 155 patients were randomised (combination: 78; osimertinib: 77). At data cut-off of 22 February 2021, median follow-up was 33.8 months [interquartile range (IQR): 26.5-37.6 months] and 129 (83.2%) PFS events were reported in the intention-to-treat population. There was no difference in median PFS between the combination [15.4 months; 95% confidence interval (CI) 9.2-18.0 months] and osimertinib arm (12.3 months; 95% CI 6.2-17.2 months; stratified log-rank P = 0.83), [hazard ratio (HR) = 0.96; 95% CI 0.68-1.37]. Median OS was 24.0 months (95% CI 17.8- 32.1 months) in the combination arm and 24.3 months (95% CI 16.9-37.0 months) in the osimertinib arm (stratified log-rank P = 0.91), (HR = 1.03; 95% CI 0.67-1.56). Exploratory analysis revealed a significant interaction of smoking history with treatment for PFS (adjusted P = 0.0052) with a HR of 0.52 (95% CI 0.30-0.90) for smokers, and 1.47 (95% CI 0.92-2.33) for never smokers. ORR was 55% in both arms and the median time to treatment failure was significantly shorter in the combination than in the osimertinib arm, 8.2 months versus 10.8 months, respectively (P = 0.0074). Safety of osimertinib and bevacizumab was consistent with previous reports with grade >= 3 treatment-related AEs (TRAEs) reported in 47% and 18% of patients on combination and osimertinib alone, respectively. Conclusions: No difference in PFS was observed between osimertinib plus bevacizumab and osimertinib alone. Grade >= 3 TRAEs were more common in patients on combination.

Published
2022

5. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

Author

B. Sierra-Rodero, C. Martínez-Toledo, M. Molina-Alejandre, V. Calvo, E. Nadal, B. Massuti Sureda, R. García Campelo, C. Gonzalez Ojea, A. Martinez-Marti, M. Domine Gomez, S. Ponce Aix, M.A. Insa Molla, J. De Castro Carpeno, M. Majem, I.C. Barneto Aranda, D. Rodriguez-Abreu, E. del Barco, M. Cobo Dols, M. Provencio Pulla, and A. Cruz-Bermudez

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2023

7. EP16.04-014 NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma

Author

Clemente, M. Blanco, primary, García, B. Núñez, additional, Calvo de Juan, V., additional, Lourdy, A. Collazo, additional, Díaz, Y. Garitaonaindía, additional, Cutillas, M. Martínez, additional, Puchol, C. Traseira, additional, Noya, R. Aguado, additional, Ceballos, G. Visedo, additional, González, S.C. González, additional, García, M. Méndez, additional, González, J.C. Sánchez, additional, Sánchez de Ibargüen, B. Cantos, additional, Parejo, C., additional, and Pulla, M. Provencio, additional

Published
2022
Full Text
View/download PDF

8. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

Casarrubios, M., primary, Cruz-Bermudez, A., additional, Sierra-Rodero, B., additional, Martinez, C., additional, Nadal, E., additional, Insa Molla, M.A., additional, Martinez, J. Mosquera, additional, Ojea, C. Gonzalez, additional, Gomez, M. Domine, additional, Tarruella, M. Majem, additional, Abreu, D. Rodriguez, additional, Martinez-Marti, A., additional, De Castro Carpeno, J., additional, Dols, M. Cobo, additional, Vivanco, G. Lopez, additional, Caro, R. Bernabe, additional, Segarra, N. Vinolas, additional, Aranda, I.C. Barneto, additional, Sureda, B. Massuti, additional, and Pulla, M. Provencio, additional

Published
2022
Full Text
View/download PDF

9. LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

Author

Deutsch, J.S., primary, Cimino-Mathews, A., additional, Thompson, E.D., additional, Wang, D., additional, Anders, R.A., additional, Gabrielson, E., additional, Illei, P., additional, Jedrych, J., additional, Danilova, L., additional, Spicer, J., additional, Pulla, M. Provencio, additional, Forde, P.M., additional, Pandya, D., additional, Tran, M.P., additional, Fiore, J., additional, Devas, V., additional, Cottrell, T.R., additional, Baras, A.S., additional, and Taube, J.M., additional

Published
2022
Full Text
View/download PDF

11. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816

Author

N. Girard, M. Provencio-Pulla, J. Spicer, J.M. Taube, C. Martin, D.R. Spigel, C. Wang, S. Lu, T. Mitsudomi, M.M. Awad, E. Felip, J.R. Brahmer, S. Broderick, S.J. Swanson, K. Kerr, L. Li, J. Cai, J. Bushong, P. Tran, and P.M. Forde

Subjects
Pulmonary and Respiratory Medicine
Published
2023

12. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Author

Linda Coate, C.M. Yeo, G. Dimopoulou, J. de Castro, H. Roschitzki-Voser, Martin Früh, Solange Peters, E. Nadal, Rolf A. Stahel, S.M.S. Hashemi, Ross A. Soo, R. Bernabé, M. Provencio, Byoung Chul Cho, M.A. Sala, Sinead Cuffe, Barbara Ruepp, J-Y. Han, R. Garcia Campelo, and Enric Carcereny

Subjects
Booster (rocketry), biology, Bevacizumab, business.industry, non-small cell lung cancer (NSCLC), Phases of clinical research, Hematology, medicine.disease, T790M, Second line, Oncology, Cancer research, biology.protein, Medicine, Osimertinib, Epidermal growth factor receptor, business, medicine.drug
Published
2021

13. 1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)

Author

E. Nadal, M.T. Moran Bueno, D. Rodriguez Abreu, Z. Vidales Sepulveda, M.A. Sala Gonzalez, M. Antonanzas Basa, J.J. Garcia Gonzalez, P. Diz Tain, M. Martinez Kareaga, G. Lopez Vivanco, J. Baena Espinar, B. Campos Balea, D. Cumplido Buron, S. Cerezo Gonzalez, A. Diaz, M. Guirado, X. Mielgo Rubio, O.J. Juan Vidal, M. Saigi Morgui, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

16. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

Author

M. Provencio, R. Serna, E. Nadal, J.L. Glez Larriba, A. Martínez-Martí, R. Bernabé, J. Bosch-Barrera, C. Garcia Benito, V. Calvo, A. Insa, S. Ponce, N. Reguart, J. De Castro, B. Massutí, R. Palmero, C. Aguado de la Rosa, J. Mosquera, M. Cobo, A. Aguilar, G. López Vivanco, C. Camps, F. Hernando Trancho, R. López Castro, T. Moran, I. Barneto, D. Rodríguez-Abreu, and A. Romero

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

22. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816

Author

E. Felip, C. Wang, T-E. Ciuleanu, G. Saylors, F. Tanaka, K-N. Chen, H. Ito, N. Girard, S. Lu, M. Provencio Pulla, T. Mitsudomi, M. Awad, P.M. Forde, R. Lawrance, F. Taylor, G. Worthy, S.I. Blum, L. Vo, J.L. Cai, and J. Spicer

Subjects
Oncology, Hematology
Published
2022

23. LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

Author

J.S. Deutsch, A. Cimino-Mathews, E.D. Thompson, D. Wang, R.A. Anders, E. Gabrielson, P. Illei, J. Jedrych, L. Danilova, J. Spicer, M. Provencio Pulla, P.M. Forde, D. Pandya, M.P. Tran, J. Fiore, V. Devas, T.R. Cottrell, A.S. Baras, and J.M. Taube

Subjects
Oncology, Hematology
Published
2022

24. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

Author

S. Hernandez, J.L. Rodriguez Carrillo, A. Caminoa, A. Benito, R. Martinez, M. Alonso, S. Clave, E. Arriola, I. Esteban-Rodriguez, J. De Castro, I. Sansano, E. Felip, I. Abdulkader, J. Garcia, F. Rojo, M. Domine, C. Teixido, N. Reguart, D. Compañ, A. Insa, N. Mancheño, S. Palanca, O. Juan, N. Baixeras, E. Nadal, M. Cebollero, A. Calles, P. Martin, C. Salas, M. Provencio, I. Aranda, B. Massuti, L. Lopez-Vilaro, M. Majem, P. Garrido, L. Paz-Ares, F. Lopez-Rios, and E. Conde

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

25. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial

Author

M. Casarrubios, A. Cruz-Bermúdez, B. Sierra-Rodero, C. Martinez, E. Nadal, V. Calvo, A. Insa, M.d.R. García- Campelo, C. Gonzalez Ojea, M. Dómine, M. Majem, D. Rodríguez-Abreu, A. Martínez-Martí, J. De Castro Carpeño, M. Cobo, G. López-Vivanco, E. Del Barco, R. Bernabé, B. Massutí, and M. Provencio

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

27. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, C. Martinez, E. Nadal, M.A. Insa Molla, J. Mosquera Martinez, C. Gonzalez Ojea, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez Abreu, A. Martinez-Marti, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, R. Bernabe Caro, N. Vinolas Segarra, I.C. Barneto Aranda, B. Massuti Sureda, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

29. Impact of Covid-19 in the field of oncology

Author

Virginia Calvo, M. Provencio, and Ana Collazo-Lorduy

Subjects
Physics, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Field (physics), medicine, Medical physics, General Medicine
Abstract

The outbreak of the new coronavirus disease (COVID-19) has become the greatest threat to public health worldwide. Oncological patients have an increased risk of infection due to their oncological disease, which supresses the immune system and mielosupressive effects of antincancer treatments. Throughout this article, the impact of COVID-19 in the oncological field will be reviewed, centering in diagnosis (susceptibility, differential diagnoses, delays in diagnosis in post-COVID era, triage systems); treatment (treatment of COVID-19 infection, surgeries, oncological treatments); impact in mortality and emotional impact. Maintaining quality of care in patients as vulnerable as cancer patients is a huge challenge in the face of possible outbreaks or future times when we have to face living with the infection but maintaining quality standards in healthcare.

Published
2020

30. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Author

S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, Pulmonary medicine, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, University of Zurich, and Stahel, R A

Subjects
Male, medicine.medical_specialty, Lung Neoplasms, 2720 Hematology, MULTICENTER, 610 Medicine & health, Ipilimumab, Randomised clinical trial, randomised clinical trial, 1ST-LINE NIVOLUMAB, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, small-cell lung cancer, Humans, RECURRENT, ipilimumab, Lung cancer, nivolumab, Limited disease, Performance status, Small cell lung cancer, business.industry, Standard treatment, Hazard ratio, PLUS IPILIMUMAB, SCLC, Hematology, Chemoradiotherapy, Middle Aged, medicine.disease, OPEN-LABEL, Nivolumab, Oncology, 10032 Clinic for Oncology and Hematology, limited disease, CHECKMATE 032, 2730 Oncology, Female, Prophylactic cranial irradiation, business, medicine.drug
Abstract

BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATIENTS AND METHODS: STIMULI is a 1:1 randomised phase II trial aiming to demonstrate superiority of consolidation combination immunotherapy versus observation after chemo-radiotherapy plus PCI (protocol amendment-1). Consolidation immunotherapy consisted of four cycles of nivolumab [1 mg/kg, every three weeks (Q3W)] plus ipilimumab (3 mg/kg, Q3W), followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months. Patient recruitment closed prematurely due to slow accrual and the statistical analyses plan was updated to address progression-free survival (PFS) as the only primary endpoint. RESULTS: Of the 222 patients enrolled, 153 were randomised (78: experimental; 75: observation). Among the randomised patients, median age was 62 years, 60% males, 34%/65% current/former smokers, 31%/66% performance status (PS) 0/1. Up to 25 May 2020 (median follow-up 22.4 months), 40 PFS events were observed in the experimental arm, with median PFS 10.7 months [95% confidence interval (CI) 7.0-not estimable (NE)] versus 42 events and median 14.5 months (8.2-NE) in the observation, hazard ratio (HR)= 1.02 (0.66-1.58), two-sided P= 0.93. With updated follow-up (03 June 2021; median: 35 months), median OS was not reached in the experimental arm, while it was 32.1 months (26.1-NE) in observation, with HR= 0.95 (0.59-1.52), P= 0.82. In the experimental arm, median time-to-treatment-discontinuation was only 1.7 months. CTCAE v4 grade =3 adverse events were experienced by 62% of patients in the experimental and 25% in the observation arm, with 4 and 1 fatal, respectively. CONCLUSIONS: The STIMULI trial did not meet its primary endpoint of improving PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in LD-SCLC. A short period on active treatment related to toxicity and treatment discontinuation likely affected the efficacy results.

Published
2021

31. 42P Real-life data on treatment with poly (ADP-ribose) polymerase inhibitor (iPARP), in patients over 65 years of age with ovarian cancer: A current need

Author

M. Martinez Cutillas, Y. Garitaonaindia Diaz, B. Nunez Garcia, M. Blanco Clemente, C. Traseira Puchol, R. Aguado, G. Visedo, A. Gónzalez Sánchez, D.I. Ruiz de Domingo, M.M. Sánchez Del Corral, M.A. Gonzalez Del Alba Baamonde, J.C. Sanchez Gonzalez, B. Cantos Sanchez de Ibarguen, M. Mendez Garcia, M. Provencio Pulla, and C. Maximiano Alonso

Subjects
Oncology, Hematology
Published
2022

33. P84.16 Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer

Author

A. Sánchez, M. Provencio, A. Morito, Manuel Martínez, A. Collazo, Virginia Calvo, B. Nunez-Garcia, M. Blanco Clemente, B. Menchen, R. Aguado, C. Traseira, F. Franco, Y. Garitaonaindia, and G. Visedo

Subjects
Pulmonary and Respiratory Medicine, Oncology, Oncogene, business.industry, medicine, Cancer research, Treatment options, Non small cell, Lung cancer, medicine.disease, business
Published
2021

34. P09.12 SARS- CoV2 Impact in a Spanish Lung Cancer Cohort?

Author

B. Nunez-Garcia, B. Nuñez-Garcia, A. Morito, M. Martínez, C. Traseira, R. Aguado, Y. Garitaonaindía, G. Visedo, F. Franco, V. Calvo, and M. Provencio

Subjects
Pulmonary and Respiratory Medicine, 2019-20 coronavirus outbreak, Oncology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Cohort, Medicine, business, Lung cancer, medicine.disease, Virology, Article
Published
2021

35. P25.06 Malignant Pleural Mesothelioma: Patient Characteristics, Treatments and Outcomes from a Spanish Center

Author

M. Provencio, C. Alfaro, A. Morito, Virginia Calvo, G. Visedo, Manuel Martínez, A. Collazo, F. Franco, Y. Garitaonaindía, B. Nunez-Garcia, C. Traseira, R. Aguado, M. Blanco Clemente, and J. Martin

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, Pleural mesothelioma, business.industry, medicine, Patient characteristics, Center (algebra and category theory), Radiology, business
Published
2021

36. EP16.04-014 NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma

Author

M. Blanco Clemente, B. Núñez García, V. Calvo de Juan, A. Collazo Lourdy, Y. Garitaonaindía Díaz, M. Martínez Cutillas, C. Traseira Puchol, R. Aguado Noya, G. Visedo Ceballos, S.C. González González, M. Méndez García, J.C. Sánchez González, B. Cantos Sánchez de Ibargüen, C. Parejo, and M. Provencio Pulla

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

37. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain

Author

B. Massutí, E. Nadal, C. Camps, E. Carcereny, M. Cobo, M. Domine, M.R. Garcia-Campelo, J.L. Gonzalez-Larriba, M. Guirado, F. Hernando-Trancho, D. Rodriguez-Abreu, A. Sanchez, I. Sullivan, and M. Provencio

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

41. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

Author

A. Romero, R. Serna, E. Nadal, J.L. Glez Larriba, A. Martínez-Martí, R. Bernabé, J. Bosch-Barrera, A. Garrido Fernandez, V. Calvo, A. Insa, S. Ponce, N. Reguart, J. De Castro, B. Massutí, R. Palmero, C. Aguado de la Rosa, J. Mosquera, M. Cobo, A. Aguilar, G. López Vivanco, C. Camps, F. Hernando Trancho, R. Lopez Castro, T. Moran, I. Barneto, D. Rodríguez-Abreu, A. Cruz, and M. Provencio

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

42. Résultats chirurgicaux de l’essai de phase 3 CheckMate 816 (CM 816) : Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néo-adjuvant du cancer bronchique non à petites cellules (CBNPC) résécable

Author

N. Girard, J. Spicer, C. Wang, F. Tanaka, G.B. Saylors, K.N. Chen, M. Liberman, E. Vokes, S. Lu, M. Provencio, T. Mitsudomi, M.M. Awad, E. Felip, P.M. Forde, S.J. Swanson, J.R. Brahmer, K. Kerr, C. Dorange, J. Cai, and S. Broderick

Subjects
Pulmonary and Respiratory Medicine
Published
2022

43. Author response for 'NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment'

Author

Bartomeu Massuti, Manuel Dómine Gomez, Roberto Serna-Blasco, Virginia Calvo, Magdalena Arnal, Noemí Reguart, Carlos Camps, Atocha Romero, Dietmar Fernández‐Orth, Rosario García-Campelo, Eloisa Jantus-Lewintre, Estela Sánchez-Herrero, Silvia Calabuig-Fariñas, Sandra Sanz-Moreno, M. Provencio, Jose Miguel Sanchez, Vadym Ivanchuk, and Víctor González‐Rumayor

Subjects
business.industry, Cancer research, Profiling (information science), Medicine, Liquid biopsy, business
Published
2021

44. 2133P Sleep disorders: Evolution in time in early breast cancer (EBC)

Author

Cantos, B., Gonzalez, J.C. Sanchez, Garcia, M. Mendez, Garcia, B. Nunez, Clemente, M. Blanco, Parejo, C., Campos, M., Morilla, B. Rodriguez, Pagan, P.F. Almaida, González, S.C. González, Puchol, C. Traseira, Cutillas, M. Martinez, Aguado, R., Díaz, Y. Garitaonaindía, Sánchez, A. González, Ruiz de Domingo, D.I., del Corral, M.M. Sánchez, Redondo, I., Torrente, M., and Pulla, M. Provencio

Published
2023
Full Text
View/download PDF

45. 2070P Assessment of healthy lifestyle habits in breast cancer patients

Author

Sanchez, J.C., Cantos, B., Garcia, M. Mendez, Garcia, B. Nunez, Clemente, M. Blanco, Parejo, C., Campos, M., Morilla, B. Rodriguez, Pagan, P.F. Almaida, González, S.C. González, Puchol, C. Traseira, Cutillas, M. Martinez, Aguado, R., Díaz, Y. Garitaonaindía, Sánchez, A. González, Ruiz de Domingo, D.I., Sánchez del Corral, M.M., Redondo, I., Torrente, M., and Pulla, M. Provencio

Published
2023
Full Text
View/download PDF

47. P40.10 Brain Metastases in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. Real World Data From a Tertiary Hospital in Spain

Author

F. Franco, Y. Garitaonaindia, C. Traseira, Virginia Calvo, A. Collazo-Lorduy, M. Provencio, and M. Martínez-Cutillas

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunotherapy, medicine.disease, Internal medicine, medicine, In patient, Non small cell, Lung cancer, business, Real world data
Published
2021

48. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

Author

J.L. González Larriba, R. Bernabé, B. Massuti, D. Rodriguez Abreu, R. López-Castro, J. Mosquera, M. Cucurull, Manuel Domine, Ana Ortega, Oscar Juan, M. Provencio, M. Cobo, A. Collazo-Lorduy, V. Calvo, M. Guirado, Enric Carcereny, M. Martínez-Cutillas, E. Del Barco, Carlos Camps, J. Bosch Barrera, Gustavo Benítez, and C. Gonzalez Ojeda

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, biology, business.industry, Cancer, medicine.disease, Transthyretin, Internal medicine, biology.protein, Medicine, Family history, business, Lung cancer
Published
2021

49. P40.12 Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors

Author

B. De La Puente, C. Traseira, M. Martínez-Cutillas, R. Aguado, Y. Garitaonaindia, V. Calvo, M. Provencio, A. Collazo-Lorduy, G. Visedo, M. Torrente, M. Blanco Clemente, A. Morito, and F. Franco

Subjects
Pulmonary and Respiratory Medicine, Cardiotoxicity, Immune system, Oncology, business.industry, Cancer research, medicine, Lung cancer, medicine.disease, business
Published
2021

50. P31.03 The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain

Author

M. Martínez-Cutillas, R. Aguado, Virginia Calvo, F. Franco, Y. Garitaonaindia, L. Cudero, M. Provencio, A. Collazo-Lorduy, and C. Traseira

Subjects
Pulmonary and Respiratory Medicine, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Thoracic Tumor, Unit (housing), Oncology, P31 Management of Lung Cancer in the Era of Covid-19 - Impact of Covid-19 in Lung Cancer Management, Pandemic, Emergency medicine, medicine, business
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results